Lanadelumab - Shire

Drug Profile

Lanadelumab - Shire

Alternative Names: Anti-plasma kallikrein mAb; Anti-plasma kallikrein monoclonal antibody; DX-2930; Lanadelumab; SHP 643

Latest Information Update: 09 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dyax
  • Developer Shire
  • Class Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Immunomodulators; Plasma-kallikrein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Hereditary angioedema
  • Preclinical Diabetic macular oedema

Most Recent Events

  • 03 Mar 2018 Updated efficacy and adverse events data from the phase III HELP trial in Hereditary angioedema released by Shire
  • 28 Feb 2018 Shire expects filing acceptance and approval of lanadelumab for Hereditary angioedema in USA in 2018
  • 28 Feb 2018 Shire expects filing acceptance of lanadelumab for Hereditary angioedema in the European Union in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top